Validation experiment designed to validate causal mechanisms targeting ATP in human. Primary outcome: Preservation of TH+ striatal fiber density with PGC-1alpha overexpression vs. controls
Description
Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease
Background and Rationale
Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra, with synaptic terminals in the striatum being the earliest sites of pathology. Mitochondrial dysfunction is a central mechanism in PD pathogenesis, contributing to synaptic energy deficits and oxidative stress that precipitate neurodegeneration. This validation study tests the therapeutic potential of enhancing mitochondrial biogenesis specifically at dopaminergic synapses through targeted overexpression of PGC-1alpha (PPARGC1A), the master regulator of mitochondrial biogenesis. The experimental design employs a well-established 6-OHDA lesion model in C57BL/6 mice to recapitulate key features of PD neurodegeneration. AAV-mediated gene delivery allows selective targeting of nigrostriatal dopaminergic neurons with PGC-1alpha or control vectors, followed by neurotoxin-induced lesioning to assess neuroprotective efficacy....
Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease
Background and Rationale
Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra, with synaptic terminals in the striatum being the earliest sites of pathology. Mitochondrial dysfunction is a central mechanism in PD pathogenesis, contributing to synaptic energy deficits and oxidative stress that precipitate neurodegeneration. This validation study tests the therapeutic potential of enhancing mitochondrial biogenesis specifically at dopaminergic synapses through targeted overexpression of PGC-1alpha (PPARGC1A), the master regulator of mitochondrial biogenesis. The experimental design employs a well-established 6-OHDA lesion model in C57BL/6 mice to recapitulate key features of PD neurodegeneration. AAV-mediated gene delivery allows selective targeting of nigrostriatal dopaminergic neurons with PGC-1alpha or control vectors, followed by neurotoxin-induced lesioning to assess neuroprotective efficacy. Comprehensive phenotyping includes behavioral assessments (rotational behavior, forelimb asymmetry), neurochemical analysis (striatal dopamine content, ATP levels), morphological quantification (TH+ fiber stereology, mitochondrial ultrastructure), and functional mitochondrial assays (membrane potential, respiratory chain activity). The innovation lies in the synapse-specific targeting approach and multi-modal assessment combining traditional histological methods with cutting-edge single-synapse proteomics to directly quantify mitochondrial protein enrichment at individual striatal boutons. This study addresses a critical knowledge gap regarding whether mitochondrial enhancement can preserve synaptic integrity in neurodegenerative disease, potentially informing novel therapeutic strategies that target the earliest sites of pathology before irreversible neuronal loss occurs.
This experiment directly tests predictions arising from the following hypotheses:
GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitochondrial transfer
Experimental Protocol
Phase 1 (Weeks 1-4): Stereotaxic injection of AAV9-PGC1alpha or AAV9-GFP control vectors (1x10^12 vg/ml, 2μl) into substantia nigra of 8-week-old male C57BL/6 mice (n=30/group). Coordinates: AP -3.1mm, ML ±1.2mm, DV -4.2mm from bregma. Phase 2 (Weeks 5-11): Recovery and transgene expression period with weekly weight monitoring. Phase 3 (Week 12): Unilateral 6-OHDA lesion (8μg/2μl in 0.02% ascorbic acid/saline) into medial forebrain bundle (AP -0.7mm, ML +1.2mm, DV -7.8mm). Desipramine (25mg/kg IP) administered 30 minutes prior to protect noradrenergic terminals. Phase 4 (Weeks 13-16): Behavioral testing including apomorphine-induced rotation (0.5mg/kg SC, rotations counted for 60 minutes) and cylinder test for forelimb asymmetry (100 contacts scored). Phase 5 (Weeks 17-24): Terminal assessments with tissue collection for HPLC analysis of striatal dopamine/metabolites, immunohistochemical quantification of TH+ fibers using unbiased stereology, transmission electron microscopy for synaptic mitochondrial morphometry, JC-1 staining for mitochondrial membrane potential, ATP bioluminescence assays, and spectrophotometric analysis of respiratory chain complex I-IV activities. Phase 6: Single-synapse mass spectrometry of FACS-sorted striatal synaptic boutons using established protocols for mitochondrial protein quantification.
Expected Outcomes
PGC-1alpha overexpression will preserve 45-50% of TH+ striatal fiber density at 24 weeks post-lesion compared to <15% in control groups (p<0.001, effect size d>2.0)
Behavioral improvement in PGC-1alpha group with 60-70% reduction in apomorphine-induced contralateral rotations versus controls and restoration of forelimb use symmetry to >80% of baseline (p<0.01)
Striatal dopamine content will be maintained at 35-40% of intact levels in PGC-1alpha mice compared to <10% in controls, with proportional preservation of DOPAC and HVA metabolites
Mitochondrial function enhancement evidenced by 2-3 fold increase in synaptic mitochondrial density, sustained membrane potential (JC-1 red/green ratio >1.5), and ATP levels maintained at >60% of controls
Respiratory chain complex activities (particularly Complex I) will show 40-50% preservation in PGC-1alpha group versus <20% in lesioned controls
Single-synapse proteomics will reveal 3-5 fold enrichment of key mitochondrial biogenesis proteins (TFAM, NRF1, cytochrome c oxidase subunits) in PGC-1alpha treated terminals
Success Criteria
Primary endpoint: ≥40% preservation of TH+ striatal fiber density in PGC-1alpha group versus ≤15% in controls with statistical significance p<0.01
Functional improvement: ≥50% reduction in apomorphine-induced rotational asymmetry and restoration of cylinder test performance to within 20% of baseline values
Neurochemical preservation: Striatal dopamine content maintained at ≥30% of intact hemisphere levels compared to <15% in control groups
Mitochondrial enhancement: Significant increases in synaptic mitochondrial density (≥2-fold), preserved membrane potential, and ATP levels >50% above lesioned controls
Mechanistic validation: Demonstration of enhanced mitochondrial protein expression at individual synapses with ≥2-fold enrichment of biogenesis markers
Consistency across timepoints: Beneficial effects maintained from 16 to 24 weeks with stable or improving trends in all primary measures
TARGET GENE
ATP
MODEL SYSTEM
human
ESTIMATED COST
$2,730,000
TIMELINE
35 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Preservation of TH+ striatal fiber density with PGC-1alpha overexpression vs. controls
Phase 1 (Weeks 1-4): Stereotaxic injection of AAV9-PGC1alpha or AAV9-GFP control vectors (1x10^12 vg/ml, 2μl) into substantia nigra of 8-week-old male C57BL/6 mice (n=30/group). Coordinates: AP -3.1mm, ML ±1.2mm, DV -4.2mm from bregma. Phase 2 (Weeks 5-11): Recovery and transgene expression period with weekly weight monitoring. Phase 3 (Week 12): Unilateral 6-OHDA lesion (8μg/2μl in 0.02% ascorbic acid/saline) into medial forebrain bundle (AP -0.7mm, ML +1.2mm, DV -7.8mm). Desipramine (25mg/kg IP) administered 30 minutes prior to protect noradrenergic terminals. Phase 4 (Weeks 13-16): Behavioral testing including apomorphine-induced rotation (0.5mg/kg SC, rotations counted for 60 minutes) and cylinder test for forelimb asymmetry (100 contacts scored).
...
Phase 1 (Weeks 1-4): Stereotaxic injection of AAV9-PGC1alpha or AAV9-GFP control vectors (1x10^12 vg/ml, 2μl) into substantia nigra of 8-week-old male C57BL/6 mice (n=30/group). Coordinates: AP -3.1mm, ML ±1.2mm, DV -4.2mm from bregma. Phase 2 (Weeks 5-11): Recovery and transgene expression period with weekly weight monitoring. Phase 3 (Week 12): Unilateral 6-OHDA lesion (8μg/2μl in 0.02% ascorbic acid/saline) into medial forebrain bundle (AP -0.7mm, ML +1.2mm, DV -7.8mm). Desipramine (25mg/kg IP) administered 30 minutes prior to protect noradrenergic terminals. Phase 4 (Weeks 13-16): Behavioral testing including apomorphine-induced rotation (0.5mg/kg SC, rotations counted for 60 minutes) and cylinder test for forelimb asymmetry (100 contacts scored). Phase 5 (Weeks 17-24): Terminal assessments with tissue collection for HPLC analysis of striatal dopamine/metabolites, immunohistochemical quantification of TH+ fibers using unbiased stereology, transmission electron microscopy for synaptic mitochondrial morphometry, JC-1 staining for mitochondrial membrane potential, ATP bioluminescence assays, and spectrophotometric analysis of respiratory chain complex I-IV activities. Phase 6: Single-synapse mass spectrometry of FACS-sorted striatal synaptic boutons using established protocols for mitochondrial protein quantification.
Expected Outcomes
PGC-1alpha overexpression will preserve 45-50% of TH+ striatal fiber density at 24 weeks post-lesion compared to <15% in control groups (p<0.001, effect size d>2.0)
Behavioral improvement in PGC-1alpha group with 60-70% reduction in apomorphine-induced contralateral rotations versus controls and restoration of forelimb use symmetry to >80% of baseline (p<0.01)
Striatal dopamine content will be maintained at 35-40% of intact levels in PGC-1alpha mice compared to <10% in controls, with proportional preservation of DOPAC and HVA metabolites
Mitochondrial function enhancement evidenced by 2
...
PGC-1alpha overexpression will preserve 45-50% of TH+ striatal fiber density at 24 weeks post-lesion compared to <15% in control groups (p<0.001, effect size d>2.0)
Behavioral improvement in PGC-1alpha group with 60-70% reduction in apomorphine-induced contralateral rotations versus controls and restoration of forelimb use symmetry to >80% of baseline (p<0.01)
Striatal dopamine content will be maintained at 35-40% of intact levels in PGC-1alpha mice compared to <10% in controls, with proportional preservation of DOPAC and HVA metabolites
Mitochondrial function enhancement evidenced by 2-3 fold increase in synaptic mitochondrial density, sustained membrane potential (JC-1 red/green ratio >1.5), and ATP levels maintained at >60% of controls
Respiratory chain complex activities (particularly Complex I) will show 40-50% preservation in PGC-1alpha group versus <20% in lesioned controls
Single-synapse proteomics will reveal 3-5 fold enrichment of key mitochondrial biogenesis proteins (TFAM, NRF1, cytochrome c oxidase subunits) in PGC-1alpha treated terminals
Success Criteria
Primary endpoint: ≥40% preservation of TH+ striatal fiber density in PGC-1alpha group versus ≤15% in controls with statistical significance p<0.01
Functional improvement: ≥50% reduction in apomorphine-induced rotational asymmetry and restoration of cylinder test performance to within 20% of baseline values
Neurochemical preservation: Striatal dopamine content maintained at ≥30% of intact hemisphere levels compared to <15% in control groups
Mitochondrial enhancement: Significant increases in synaptic mitochondrial density (≥2-fold), preserved membrane potential, and ATP levels >50% above
...
Primary endpoint: ≥40% preservation of TH+ striatal fiber density in PGC-1alpha group versus ≤15% in controls with statistical significance p<0.01
Functional improvement: ≥50% reduction in apomorphine-induced rotational asymmetry and restoration of cylinder test performance to within 20% of baseline values
Neurochemical preservation: Striatal dopamine content maintained at ≥30% of intact hemisphere levels compared to <15% in control groups
Mitochondrial enhancement: Significant increases in synaptic mitochondrial density (≥2-fold), preserved membrane potential, and ATP levels >50% above lesioned controls
Mechanistic validation: Demonstration of enhanced mitochondrial protein expression at individual synapses with ≥2-fold enrichment of biogenesis markers
Consistency across timepoints: Beneficial effects maintained from 16 to 24 weeks with stable or improving trends in all primary measures